Table 2 Participant outcomes to be evaluated before and after the HPV-based trial
Outcome | Outcome definitions | Current VIA programme | HPV trial |
|---|---|---|---|
Reach | a) Invitation rate: % invited out of eligible b) Screening participation rate: % screened out of invited c) Follow-up rate for assessment: % assessed out of screen positives d) Treatment rate: % completed treatment for pre-cancer/initiated cancer treatment, out of assessed e) Representativeness: key differences between invited vs not invited, screened and not screened, followed/treated vs those not followed up/treated f) Barriers for non-participation | Facility assessment survey checklist Qualitative study | Screening registry for trial Qualitative study |
Acceptability | a) Acceptability of screening and associated treatment | Qualitative study | Qualitative study Feedback surveys |
Effectiveness | a) Well managed: % of women invited who are screened and receive appropriate treatment and advice b) Number of pre cancer and cancers detected by screening and by clinical presentation c) Adverse events of screening among participants including social/economic d) Any other/unexpected health benefits associated with screening | Facility assessment survey checklist Qualitative study | Screening registry for trial Feedback surveys Qualitative study |